Back to Network
10
Shared Docs
10
Same-Page
10 / 10
Mentions
Document Mentions (10 shared documents)
2 mentions1 same-page
Page ?Same page
capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1 list of best Investment Ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where sc
TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the le
2 mentions1 same-page
Page ?Same page
pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca
TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAM reaffirming BUY after rontier reported its first post-Verizon assets merger results. FTR's ea nings miss was due to a decline in the lega
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l
Sponsored
2 mentions1 same-page
Page ?Same page
l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where
ositioning in generic=pharma where scale and product diversity are increasingly important. TEVA =emains one of our top picks in Spec Pharma.<=span> Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a=decline in the l
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l
2 mentions1 same-page
Page ?Same page
pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l
Sponsored
Mutual Connections (32)
Entities connected to both Teva Pharma and Frontier Comm
Jeffrey Epstein
PERSON11 w/ Teva·10 w/ Frontier
Marc Rich
PERSON11 w/ Teva·10 w/ Frontier
Paul Volcker
PERSON11 w/ Teva·10 w/ Frontier
Richard Kahn
PERSON11 w/ Teva·10 w/ Frontier
HM
Hans Mikkelsen
PERSON11 w/ Teva·10 w/ Frontier
Bloomberg L.P.
ORGANIZATION11 w/ Teva·10 w/ Frontier
Frontier Communications
ORGANIZATION11 w/ Teva·10 w/ Frontier
Chart One
ORGANIZATION11 w/ Teva·10 w/ Frontier
US Treasury ETF
ORGANIZATION11 w/ Teva·10 w/ Frontier
S&P500 ETF
ORGANIZATION11 w/ Teva·10 w/ Frontier
Investment Grade Supply
ORGANIZATION11 w/ Teva·10 w/ Frontier
Investment Grade ETF
ORGANIZATION11 w/ Teva·10 w/ Frontier
Spec Pharma
ORGANIZATION10 w/ Teva·9 w/ Frontier
Allergan
LOCATION9 w/ Teva·9 w/ Frontier
AM
Amanda
PERSON8 w/ Teva·7 w/ Frontier
PR
Pfd Return
PERSON7 w/ Teva·7 w/ Frontier
AE
Amanda Ens
PERSON7 w/ Teva·6 w/ Frontier
Non-Farm Payrolls
ORGANIZATION6 w/ Teva·6 w/ Frontier
Outlook
ORGANIZATION6 w/ Teva·6 w/ Frontier
Bloomberg: Junk Debt Keeps Climbing Despite Plunging Oil Prices
ORGANIZATION6 w/ Teva·5 w/ Frontier